This Article Full Text Full Text (PDF) Kemna et al. Additional Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (35) Citing Articles via Google Scholar Google Scholar Articles by Kemna, E. H.J.M. Articles by Swinkels, D. W. Search for Related Content PubMed PubMed Citation Articles by Kemna, E. H.J.M. Articles by Swinkels, D. W.

Hepcidin: from discovery to differential diagnosis

Department of Clinical Chemistry, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

Correspondence: Dorine W. Swinkels, Department of Clinical Chemistry 441, Radboud University Nijmegen Medical Centre, P.O. Box 9101 6500 HB Nijmegen, The Netherlands. E-mail: d.swinkels{at}akc.umcn.nl

Although iron is essential for living organisms to survive, its reactive properties require strict regulation in order to prevent toxic effects. Hepcidin, a liver produced peptide hormone, is thought to be the central regulator of body iron metabolism. Its production is mainly controlled by the erythropoietic activity of the bone-marrow, the amount of circulating and stored body iron, and inflammation. Recent reports, however, provide new hypotheses on how hepcidin might exert its regulatory function. Although hepcidin was first discovered in human urine and serum, most of our understanding of hepcidin regulation and action comes from in vitro and mice studies that often use hepcidin mRNA expression as a read out. The difficulties in carrying out studies in humans have mostly been due to the lack of suitable hepcidin assay. The recent development of assays to measure hepcidin in serum and urine has offered new opportunities to study hepcidin regulation in humans. However, for the moment, only a small number of laboratories are able to perform these assays. The aim of this review is to discuss insights into hepcidin regulation obtained from recent clinical studies in the light of findings from in vitro and mice studies. Ongoing studies in humans should provide us with more information on the etiology of iron metabolism disorders in order to create new therapeutic strategies and improve differential diagnosis protocols for these diseases.

Key words: hepcidin, iron.

This article has been cited by other articles:

				G. Bergamaschi and L. Villani Serum hepcidin: a novel diagnostic tool in disorders of iron metabolism Haematologica, December 1, 2009; 94(12): 1631 - 1633. [Full Text] [PDF]

				J. J.C. Kroot, E. H.J.M. Kemna, S. S. Bansal, M. Busbridge, N. Campostrini, D. Girelli, R. C. Hider, V. Koliaraki, A. Mamalaki, G. Olbina, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization Haematologica, December 1, 2009; 94(12): 1748 - 1752. [Abstract] [Full Text] [PDF]

				S. D. Anker, J. C. Colet, G. Filippatos, R. Willenheimer, K. Dickstein, H. Drexler, T. F. Luscher, C. Mori, B. von Eisenhart Rothe, S. Pocock, et al. Rationale and design of Ferinject(R) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia Eur J Heart Fail, November 1, 2009; 11(11): 1084 - 1091. [Abstract] [Full Text] [PDF]

				J. F. Baker and A. J. Ghio Iron homoeostasis in rheumatic disease Rheumatology, November 1, 2009; 48(11): 1339 - 1344. [Abstract] [Full Text] [PDF]

				H. P.E. Peters, C. M.M. Laarakkers, D. W. Swinkels, and J. F.M. Wetzels Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate Nephrol. Dial. Transplant., October 23, 2009; (2009) gfp546v1. [Abstract] [Full Text] [PDF]

				M. Andreani, F. C. Radio, M. Testi, C. De Bernardo, M. Troiano, S. Majore, P. Bertucci, P. Polchi, R. Rosati, and P. Grammatico Association of hepcidin promoter c.-582 A>G variant and iron overload in thalassemia major Haematologica, September 1, 2009; 94(9): 1293 - 1296. [Abstract] [Full Text] [PDF]

				M. van Deuren, J. J. C. Kroot, and D. W. Swinkels Time-course analysis of serum hepcidin, iron and cytokines in a C282Y homozygous patient with Schnitzler's syndrome treated with IL-1 receptor antagonist Haematologica, September 1, 2009; 94(9): 1297 - 1300. [Abstract] [Full Text] [PDF]

				L. Valenti, D. Girelli, G. F. Valenti, A. Castagna, G. Como, N. Campostrini, R. Rametta, P. Dongiovanni, P. Messa, and S. Fargion HFE Mutations Modulate the Effect of Iron on Serum Hepcidin-25 in Chronic Hemodialysis Patients Clin. J. Am. Soc. Nephrol., August 1, 2009; 4(8): 1331 - 1337. [Abstract] [Full Text] [PDF]

				J. J.C. Kroot, C. M.M. Laarakkers, E. H.J.M. Kemna, B. J. Biemond, and D. W. Swinkels Regulation of serum hepcidin levels in sickle cell disease Haematologica, June 1, 2009; 94(6): 885 - 887. [Full Text] [PDF]

				J. P. Karl, H. R. Lieberman, S. J. Cable, K. W. Williams, E. L. Glickman, A. J. Young, and J. P. McClung Poor Iron Status Is Not Associated with Overweight or Overfat in Non-Obese Pre-Menopausal Women J. Am. Coll. Nutr., February 1, 2009; 28(1): 37 - 42. [Abstract] [Full Text] [PDF]

				D. M Frazer and G. J Anderson Hepcidin compared with prohepcidin: an absorbing story Am. J. Clinical Nutrition, February 1, 2009; 89(2): 475 - 476. [Full Text] [PDF]

				M. A. Melis, M. Cau, R. Congiu, G. Sole, S. Barella, A. Cao, M. Westerman, M. Cazzola, and R. Galanello A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron Haematologica, October 1, 2008; 93(10): 1473 - 1479. [Abstract] [Full Text] [PDF]

				U. Kobold, T. Dulffer, M. Dangl, A. Escherich, M. Kubbies, R. Roddiger, and J. A. Wright Quantification of Hepcidin-25 in Human Serum by Isotope Dilution Micro-HPLC-Tandem Mass Spectrometry Clin. Chem., September 1, 2008; 54(9): 1584 - 1586. [Full Text] [PDF]

				D. W. Swinkels and J. F. M. Wetzels Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2450 - 2453. [Full Text] [PDF]

				K. S. Olsson and A. Norrby Comment to: Hepcidin: from discovery to differential diagnosis. Haematologica 2008; 93:90-7 Haematologica, June 1, 2008; 93(6): e51 - e51. [Full Text] [PDF]